drugset
drugset / Trial / NCT03606057

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057 ↗

Phase 1 Completed 188 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram morphology at supratherapeutic exposures in otherwise healthy overweight/obese adults after 4 weeks of treatment with JNJ 64565111 administered subcutaneously once weekly.

Timeline

Start
2018-07-13
Primary completion
2019-02-08
Completion
2019-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown — Subcutaneous
Comparator Moxifloxacin Small molecule — —

Indications

No indication recorded.